Patents by Inventor Davide Robbiani

Davide Robbiani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CROSS-SPECIFIC ANTIBODIES, USES AND METHODS FOR DISCOVERY THEREOF
    Publication number: 20250382354
    Abstract: The invention relates to antibodies, multispecific antibodies, or antigen-binding fragments thereof, specifically binding to a conserved region of a coronavirus S protein and their use in medicine, such as, in the treatment and/or prevention of a coronavirus infection. The invention further relates to methods for identifying coldspot antibodies or antigen-binding fragments thereof.
    Type: Application
    Filed: June 8, 2023
    Publication date: December 18, 2025
    Inventors: Davide ROBBIANI, Filippo BIANCHINI, Virginia CRIVELLI, Andrea CAVALLI, Luca VARANI
  • ANTIBODIES AGAINST CHEMOKINES, METHOD FOR IDENTIFYING SAID ANTIBODIES AND USES THEREOF
    Publication number: 20250298032
    Abstract: The present disclosure provides antibodies against chemokines, in particular to auto-antibodies against chemokines, nucleic acids encoding such antibodies and compositions comprising such antibodies. The present disclosure also provides a method for identifying (auto-)antibodies against chemokines, antibodies identified by said method and to the use of antibodies against chemokines as biomarkers, and for the treatment and diagnosis of diseases, such as COVID-19.
    Type: Application
    Filed: May 3, 2023
    Publication date: September 25, 2025
    Inventors: Davide ROBBIANI, Mariagrazia UGUCCIONI, Andrea CAVALLI, Jonathan MURI, Valentina CECCHINATO
  • NEUTRALIZING ANTIBODIES THAT BIND TO THE ZIKA VIRUS DOMAIN III ENVELOPE REGION
    Publication number: 20220306729
    Abstract: Antibodies to Zika virus (ZIKV) and dengue 1 virus (DENV1) are provided. The amino acid sequences of the antibodies may be modified. Methods for prophylaxis and/or therapy by administering the antibodies and combinations thereof are provided. Immunological detection methods using the antibodies are provided. Also provided are vaccine compositions which comprise peptides derived from ZIKV and DENV1.
    Type: Application
    Filed: May 19, 2022
    Publication date: September 29, 2022
    Inventors: Davide ROBBIANI, Michel NUSSENZWEIG
  • Neutralizing antibodies that bind to the zika virus domain III envelope region
    Patent number: 11370830
    Abstract: Antibodies to Zika virus (ZIKV) and dengue 1 virus (DENV1) are provided. The amino acid sequences of the antibodies may be modified. Methods for prophylaxis and/or therapy by administering the antibodies and combinations thereof are provided. Immunological detection methods using the antibodies are provided. Also provided are vaccine compositions which comprise peptides derived from ZIKV and DENV1.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: June 28, 2022
    Assignee: The Rockefeller University
    Inventors: Davide Robbiani, Michel Nussenzweig
  • COMPOSITIONS AND METHODS RELATED TO HUMAN NEUTRALIZING ANTIBODIES TO ZIKA AND DENGUE 1 VIRUS
    Publication number: 20200147199
    Abstract: Antibodies to Zika virus (ZIKV) and dengue 1 virus (DENV1) are provided. The amino acid sequences of the antibodies may be modified. Methods for prophylaxis and/or therapy by administering the antibodies and combinations thereof are provided. Immunological detection methods using the antibodies are provided. Also provided are vaccine compositions which comprise peptides derived from ZIKV and DENV1.
    Type: Application
    Filed: April 9, 2018
    Publication date: May 14, 2020
    Inventors: Davide ROBBIANI, Michel NUSSENZWEIG
  • Gene reactivation by somatic hypermutation
    Publication number: 20060080745
    Abstract: The invention provides an inactivated or attenuated gene functionally linked to a hotspot for somatic hypermutation. Inventive nucleic acids include inactivated genes operatively linked to immunoglobulin gene control elements. Embodiments of the invention include murine models of plasma cell disease and germinal center cell lymphoma.
    Type: Application
    Filed: October 11, 2005
    Publication date: April 13, 2006
    Applicant: Cornell Research Foundation, Inc.
    Inventors: P. Bergsagel, Davide Robbiani